Please login to the form below

Not currently logged in
Email:
Password:

India revokes Pfizer's patent on Sutent

Loses patent protection for kidney cancer drug after Cipla and Natco challenge

Pfizer has become the latest Western drugmaker to fall foul of India's increasingly contentious intellectual property (IP) environment, losing patent protection for its kidney cancer drug Sutent.

The country's Patent Office revoked the basic patent for Sutent (sunitinib malate) on the grounds that it did not include an inventive step, backing the position taken up by Indian drugmakers Cipla and Natco Pharma in a legal challenge to Pfizer's IP.

Cipla had argued that the inventiveness of Pfizer's patent was compromised by "structural obviousness", in other words the compound's structure could have been deduced from similar drugs already covered by earlier patents.

Pfizer said immediately it would lodge an appeal against the Patent Office's decision, which is the third defeat for a major pharma company in India in as many weeks, all involving widely-used cancer drugs.

The company sells its Sutent product for 1.96 lakh (about $3,800) for a 45-day course, and Cipla says it will make its Sunitib version available at a 10 per cent discount, according to a LiveMint report.

Last month, Bayer failed in a bid to overturn a compulsory license which removed patent protection for its Nexavar (sorafenib) cancer drug, allowing a cut-price competitor from Natco to enter the market. 

Just a few days before the Nexavar verdict Roche lost a four-year legal dispute with Cipla over patent rights to Tarceva (erlotinib), while Novartis is still in the throes of a long-running legal dispute as it tries to defend blockbuster cancer drug Glivec (imatinib) and is expecting a verdict before the end of this year.

Pfizer had already protected Sutent from a compulsory license challenge in 2008, a year after the company was awarded its patent and launched the product, and in an interview with the Business Standard said the Patent Office's latest action "raised concerns over India's commitment to protect intellectual property".

5th October 2012

From: PME

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical website. Support the...

Latest intelligence

JulAug cover image
The Chronicles of Pharma: a creative review of pharma’s journey to omnichannel
Chris Ross conducts a literary-inspired review of pharma’s pursuit of communications excellence...
The key to psoriasis innovation? Dispelling the shadow of the JAK inhibitor
Powerful therapies that can improve skin clarity dominate the psoriasis landscape, so why are most patients stuck in a cycle of ineffective topicals? Fishawack Health explores the market and reveals...
Virtual Speaker Program: A Customer Story
Learn how we helped our client develop a virtual speaker program and roll out a series of regional peer-to-peer education sessions....